Podcast
Steve Gately Joins Bourne Partners for a Deep Dive on the Future of Oncology CROs
A conversation on how specialized partners like TD2 Oncology are shaping precision medicine, global trial quality, and the next wave of advanced therapies.
Dr. Steve Gately sat down with Bourne Partners on their Deep Dive podcast to discuss how the CRO landscape is shifting and what this means for sponsors developing complex oncology programs. The conversation highlights why specialty organizations like TD2 Oncology remain essential in an environment shaped by rapid scientific progress, evolving global regulations, and rising expectations for data quality.
Steve shares how TD2 Oncology’s integrated scientific and clinical model supports precision oncology programs, the unique pressures created by global trial execution, and the growing demand for expertise in advanced modalities such as radiopharmaceuticals and antibody drug conjugates. He also touches on the advantages that focused oncology partners bring to sponsors who need fast, informed decision making throughout development.
The episode offers a clear look at how TD2 helps innovators navigate the most challenging areas of cancer drug development while keeping scientific insight, operational discipline, and patient impact at the center of every program.
